Муколитическая терапия в детском возрасте: возможности, эффективность, безопасность
DOI:
https://doi.org/10.15574/SP.2017.85.41Ключевые слова:
дети, мукоцилиарный клиренс, трахеобронхиальный секрет, муколитические препараты, ацетилцистеинАннотация
Приведены данные о возможности использования муколитических препаратов в детском возрасте. Рассматриваются механизмы образования и выведения трахеобронхиального секрета, причины нарушения мукоцилиарного клиренса. Приводится характеристика ацетилцистеина, основные механизмы действия и рекомендации по его использованию.
Библиографические ссылки
Belousov YuB, Omelyanovskiy VV. (1996). Mukoliticheskie i fitoterapevticheskie sredstva. Klinicheskaya farmakologiya bolezney organov dyihaniya. Moskva, Universum Pablishing.
Gelle NA, Malahov AB. (1999). Mukoliticheskie i protivokashlevyie sredstva v praktike pediatra (lektsiya). Detskiy doktor. 4.
Golub AV. (2012). Bakterialnyie bioplenki — novaya tsel terapii? Klin mikrobiol antimikrob himioter. 14; 1: 23—29.
Delyagin VM, Byistrova NYu. (19990. Antibakterialnyie i mukoaktivnyie preparatyi. Moskva, Altus.
Zamotaev IP. (1993). Farmakoterapiya v pulmonologii. Moskva.
Kurashov OV, Trotsevich VA. (1992). Primenenie atsetiltsisteina v kompleksnom lechenii bolnyih s ostryimi otravleniyami 1,2-dihloretanom. Vracheb. delo. 10: 109—111.
Maidannyk VH, Smiian OI, Bynda TP. (2009). Hostra pnevmoniia u ditei: klinichni varianty perebihu, diahnostyka ta likuvannia. Sumy, SumDU: 156.
Mashkovskiy MD. (2008). Lekarstvennyie sredstva. Moskva, Novaya volna.
Mizernitskiy YuL. (2005). Printsipyi terapii ostryih respiratornyih infektsiy u detey. Pulmonologiya detskogo vozrasta: problemyi i resheniya. Moskva. 5: 106—111.
Mizernitskiy YuL, Ermakova IN. (2008). Sovremennyie mukoliticheskie i otharkivayuschie sredstva v terapii ostryih respiratornyih infektsiy u detey. Vestnik pediatrich farmakol i nutritsiol. 5; 4: 53—58.
Orlova AV, Gembitskaya TE. (1999). Bronhialnyiy sekret: obrazovanie, vyivedenie, izmenenie pod vliyaniem lekarstv. Allergiya. 4.
Popova EN, Kornev BM, Reznikova KU, Kondarova OV. (2005). Patogeneticheskoe i klinicheskoe obosnovanie primeneniya N-atsetiltsisteina (Fluimitsila) pri idiopaticheskom fibroziruyuschem alveolite. Pulmonologiya. 1: 34—41.
Popova EN, Arhipov DV, Kogan EA. (2004). Rol endotelialnoy disfunktsii i neoangiogeneza v razvitii pnevmoskleroza i legochnoy gipertenzii pri obyichnoy interstitsialnoy pnevmonii. Pulmonologiya. 3: 16—22.
Simonova OI, BorisYonok OA, Bushma KM. (2011). Mukolitiki dlya detey: slozhnyie voprosyi, vazhnyie otvetyi. Voprosyi sovr pediatrii. 10; 1.
Solopov VN. (2000). Astma. Kak vernut zdorove. Moskva, Meditsina.
Tatochenko VK. (2000). Prakticheskaya pulmonologiya detskogo vozrasta (spravochnik). Moskva.
Ushkalova EA. (2007). Farmateka. 17: 30—36.
Fedoseev GB, Zhiharev SS. (1989). Osnovnyie mehanizmyi zaschityi bronholegochnoy sistemyi. Bolezni organov dyihaniya. Pod red NV Putova. 1. Moskva, Meditsina: 112—143.
Tsaregorodtsev AD, Tabolin VA. (2002). Rukovodstvo po farmakoterapii v pediatrii i detskoy hirurgii. 1: Farmakoterapiya v pediatricheskoy pulmonologii. Pod red SYu Kaganova. Moskva, Medpraktika-M.
Chikina SYu. (2005). Primenenie Fluimitsila v respiratornoy meditsine. Atmosfera Pulmonologiya i allergologiya. 3: 36—40.
Chuchalin AG, Abrosimov VN. (2000). Kashel. Ryazan.
Al-Mazrou KA, Al-Khattaf AS. (2008). Adherent biofilms in adenotonsillar diseases in children. Arch Otolaryngol Head Neck Surg. 134: 20—3.
Andersen LW, Thiis J, Kharazmi A, Rygg I. (1995). Perfusion. 10; l: 21—26. https://doi.org/10.1177/026765919501000105
Aruoma OL, Haliiwell В, Ноеу ВМ, Bucler J. (1989). Free Radic Biol Med. 6; 6:.593—597. https://doi.org/10.1016/0891-5849(89)90066-X
Vu B, Chen M, Crawford RJ et al. (2009). Bacterial extracellular polysaccharides involved in biofilm formation. Molecules. 14: 2535—54.
Badawy A, State O, Abdelgawad S. (2007). N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a crossover trial. Acta Obstet Gynecol Scand. 86(2): 218—222.
Berk M, Copolov D, Dean O et al. (2008). Biol Psychiatry. 64; 5: 361—368. https://doi.org/10.1016/j.biopsych.2008.04.022; https://doi.org/10.1016/j.biopsych.2008.03.004
Cohen M, Kofonow J, Nayak JV et al. (2009). Biofilm in chronic rhinosinusitis: a review. Am J Rhinol Allergy. 23: 255—60.
Biofilm life cycle. Montana State University Center for Biofilm Engineering. http://www.biofilm.montana.edu.
Boesgaard В, Aldershvile J, Pedersen F et al. (1991). J Cardiovas Pharmacol. 17; 6: 889—89. https://doi.org/10.1097/00005344-199106000-00005
Ceconi C, Curello S, Cargnoni A et al. (1988). J Mol Cell Cardiol. 20; 1: 5—13. https://doi.org/10.1016/S0022-2828(88)80174-3
Centers for Disease Control, California. (1997). Amanita phalloides Mushroom Poisoning. 46; 22: 489—492.
Cetinkale О, Senel О, Bulan R. (1999). Burns. 25; 2: 113—118. https://doi.org/10.1016/S0305-4179(98)00147-8; https://doi.org/10.1016/S0305-4179(98)00124-7
Foreman A, Psaltis AJ, Tan LW et al. (2009). Characterization of bacterial and fungal biofilms in chronic rhinosinusitis. Am J Rhinol Allergy. 23: 556—61.
De Flora S, Astengo M, Serra D, Bennicelli C. (1986). Cancer Lett. 32; 3: 235—241. https://doi.org/10.1016/0304-3835(86)90175-8
De Flora S, Grassi C, Carati L. (1997). Eur Respir J. 10: 1535—1541. https://doi.org/10.1183/09031936.97.10071535; PMid:9230243
Dekhuijzen PN. (2006). Ned Tijdschr Geneeskd. 150: 1222—1226.
Demedts M, Behr J, Buhl R et al. (2005). N Engl J Med. 353: 2229—2242. https://doi.org/10.1056/NEJMoa042976; PMid:16306520
Dickey DT, Muldoon LL, Doolittle ND et al. (2008). Cancer Chemother Pharmacol. 62; 2: 235—241. https://doi.org/10.1007/s00280-007-0597-2; PMid:17909806 PMCid:PMC2776068
Donlan RM, Costerton JW. (2002). Biofilms: survival mechanisms of clinically relevant microorganism. Clin Microbiol Rev. 15: 167—93.
Doroshow JH, Locker GY, Ifrim I, Myers CE. (1981). J Clin Invest. 68; 4: 1053—1064. https://doi.org/10.1172/JCI110328; PMid:7287901 PMCid:PMC370893
Droge W. (1993). Pharmacology. 46: 61—65.
Macchi A, Ardito F, Marchese A et al. (2006). Efficacy of N-acetylcisteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even if sustained by bacterial biofilms. J Chemother. 18: 507—13.
Eylar Е, Rivera-Quinones С, Molina С et al. (1993). Immunology. 5; 1: 97—101.
Ferguson CL, Cantilena LRJr. (1992). J Toxicol Clin Toxicol. 3: 34—35.
Fiorentini С, Falzano L, Rivabene R et al. (1999). FEBS Lett. 453; 1—2: 124—128. https://doi.org/10.1016/S0014-5793(99)00706-1
Flemming HC, Wingender J. (2010). The biofilm matrix. Nat Rev Microbiol. 8: 623—33.
Gordon CA, Hodges N, Marriott C. (1991). Use of slime dispersants to promote antibiotic penetration through the extracellular polisaccaride of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother. 35: 1258—60.
Hagiwara SI, Ishii Y, Kitamura S. (2000). Am J Respir Crit Care Med. 162; 1: 225—231. https://doi.org/10.1164/ajrccm.162.1.9903129; PMid:10903246
Horowitz JD, Antman EM, Lorell BH et al. (1983). Circulation. 68; 6: 1247—1253. https://doi.org/10.1161/01.CIR.68.6.1247
Hurd RW Wilder BJ, Helveston WR, Uthman BM. (1996). Neurology. 47; 5: 1264—1268.
Perez-Giraldo C, Rodriguez-Benito A, Moran FJ et al. (1997). Influence of N-acetylcysteine on formation of biofilm by Staphylococcus epidermidis. J Ant Chem. 39: 643—6.
Riise GC, Qvarfordt I, Larsson S et al. (2000). Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration. 67: 552—8.
Kay J, Chow WH, Chan TM et al. (2003). JAMA. 289: 553—558. https://doi.org/10.1001/jama.289.5.553; https://doi.org/10.1121/1.1572368
Kilty SJ, Desrosiers MY. (2008). The role of bacterial biofilms and the pathophysiology of chronic rhinosinusitis. Curr Allergy Asthma Rep. 8: 227—33.
Kou-G, Shyu C, Jun-Jack C, Peiliang V. (2002). J Am Coll Cardiol. 40: 13831388.
Lindner Н, Holier Е, Erd В. et al. (1997). Blood. 89; 6: 1931—1938.
Marenzi G, Assanelli E, Marana I et al. (2006). N Engl J Med. 354: 2773—2782. https://doi.org/10.1056/NEJMoa054209; PMid:16807414
Mattin D, Willis S, Cline D. (1990). J Amer Board Fam Pract. 3: 293—296.
Menor С, Femandez-Moreno MD, Fueyo JA et al. (2004). J Pharm Exper Therap. 311: 668-676. https://doi.org/10.1124/jpet.104.069286; PMid:15226385
Morris PE, Bernard GR. (1994). Amer J Med Sci. 307: 119—127.
MoWus P, Cotgreave IA, Berggren M. (1986). Respiration. 50; 1: 31—42.
Olson KR. (1994). Poisoning & Drug Overdose. 2nd ed. Appleton & Lange.
Orhan G, Yapici N, Yuksel M et al. (2006). Heart and Vessels. 21; 1: 42-47. https://doi.org/10.1007/s00380-005-0873-1; PMid:16440148
Paul J. (2009). Millea N-Acetylcysteine: Multiple Clinical Applications. American Family Physician. 80; 3: 265—269.
Pintucci JP, Corno S, Garotta M. (2010). Biofilms and infections of the upper respiratory tract. Eur Rev Med Pharmacol Sci. 14: 683—90. PMid:20707288
Rizk AY, Bedaiwy MA, Al-Inany HG. (2005). N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 83(2): 367—370. https://doi.org/10.1016/j.fertnstert.2004.07.960; PMid:15705376
Roederer M, Staal FJ, Ela SW et al. (1993). Pharmacology. 46: 121—129. https://doi.org/10.1159/000139037; PMid:8441760
Shaikh ZA, Zaman К, Tang W, Vu T. (1999). Toxicol Lett. l04; l—2: 137—142. https://doi.org/10.1016/S0378-4274(98)00358-0; https://doi.org/10.1016/S0300-483X(99)00012-8
Stalenhoef A, Kroon AA, Demacker PN. (1991). Lancet. 337: 491. https://doi.org/10.1016/0140-6736(91)93425-9
Sucu N, Cinel I, Unlu A et al. (2004). Surgery Today. 34; 3: 237—242. https://doi.org/10.1007/s00595-003-2699-8; PMid:14999536
Tang LD. (1991). Brit J Pharmacol. 102; 3: 601—606. https://doi.org/10.1111/j.1476-5381.1991.tb12219.x; PMid:1364825 PMCid:PMC1917948
Tariq M, Morais C, Sobki S et al. (1999). Nephr Dialysis Transpl. 14: 4923—4929. https://doi.org/10.1093/ndt/14.4.923
Tepel M, Giet M, Schwarzfeld C et al. (2000). N Engl J M. 343: 180—184. https://doi.org/10.1056/NEJM200007203430304; PMid:10900277
Thakker DR, Yagi H, Levin W et al. (1985). Ed Anders MV. Bioactivation of foreign compounds: 177—230.
Winniford MD, Kennedy PL, Wells PJ, Hillis LD. (1986). Circulation. 73; 1: 138—142. https://doi.org/10.1161/01.CIR.73.4.662; https://doi.org/10.1161/01.CIR.73.1.138
Wispriyono В, Matsuoka М, Igisu Н, Matsuno K. (1998). J Pharmacol Exp Ther. 287; l: 344-351.
Yusof M, Yildiz D, Ercal N. (1999). Toxicol Lett. 106; 1: 41—47. https://doi.org/10.1016/S0378-4274(99)00014-4
Zhao T, Liu Y. (2010). N-acetylcysteine inhibit biofilm produced by Pseudomonas aeruginosa. BMC Microbiol. 10: 140. https://doi.org/10.1186/1471-2180-10-140; PMid:20462423 PMCid:PMC2882372
